Results 21 to 30 of about 2,050 (152)

Real-world use of eravacycline for the treatment of mono- and polymicrobial infections involving Enterobacterales [PDF]

Microbiology Spectrum
Bacterial species in the Enterobacterales order are commonly encountered causative organisms in hospital-acquired infections. Furthermore, the incidence of carbapenem-resistant Enterobacterales (CRE) is a growing threat worldwide. Eravacycline (ERV) is a
Sean R. Van Helden, Ashlan J. Kunz Coyne, Sara Alosaimy, Abdalhamid M. Lagnf, Kyle C. Molina, S. Lena Kang-Birken, Kimberly C. Claeys, Mark Biagi, Justin Andrade, Alaina DeKerlegand, Melanie Rae Schrack, Tristan Gore, Madeline A. King, Benjamin M. Pullinger, Serina Tart, Athena L. V. Hobbs, Jazmin Agee, Nicholson B. Perkins, Michael P. Veve, Reese Cosimi, Shelbye R. Herbin, Bruce M. Jones, Amy K. Feehan Curley, Chloe Judd, Mohammed Al Musawa, Michael J. Rybak   +25 more
doaj   +2 more sources

Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan: A clinical microbiological study

Journal of Global Antimicrobial Resistance
Objectives: Eravacycline, a new tetracycline derivative, exhibits broad-spectrum antimicrobial susceptibility. This study aimed to comprehensively investigate in vitro activities of eravacycline, tigecycline, and ertapenem against various Gram-positive ...
Ming-Han Tsai, Chih-Jung Chen, Hsin-Ju Chang   +2 more
exaly   +3 more sources

Eravacycline as Salvage Therapy for Severe Intra-Abdominal Infections Caused by Multidrug-Resistant Acinetobacter baumannii: A Case Series [PDF]

Antibiotics
Background/Objectives: Infections due to multidrug-resistant (MDR) Acinetobacter baumannii represent a critical challenge in modern healthcare, with limited therapeutic options.
Marcello Trizzino, Giulio D’Agati, Luca Pipitò, Claudia Conti, Rossella Petrantoni, Raffaella Rubino, Antonio Anastasia, Sofia Urso, Irene Ganci, Maria Cappello, Antonio Cascio   +10 more
doaj   +2 more sources

Intrathecal combined with intravenous eravacycline for the treatment of multisite carbapenem-resistant Acinetobacter baumannii infections (intracranial, pulmonary, and bloodstream) in a post-trauma adolescent female: a case report [PDF]

Frontiers in Medicine
BackgroundCarbapenem-resistant Acinetobacter baumannii (CRAB) is a leading cause of hospital-acquired infection among critically ill patients, with extremely limited therapeutic options, particularly for central nervous system (CNS) infections ...
Jieluan Lu, Junjie Zhong, Wenbing Qiu, Qian Zhang   +3 more
doaj   +2 more sources

Combating resistant pathogens: exploring the efficacy of eravacycline utilization in multidrug-resistant infections [PDF]

Microbiology Spectrum
Eravacycline, FDA-approved for complicated intra-abdominal infections, is increasingly used off-label for multidrug-resistant infections, including carbapenem-resistant Enterobacterales, Stenotrophomonas maltophilia, and carbapenem-resistant ...
Kiara Patino, Ryan Vathy, Ben Albrecht, Sujit Suchindran, Sarah B. Green   +4 more
doaj   +2 more sources

In vitro activities of eravacycline against clinical bacterial isolates: a multicenter study in Guangdong, China [PDF]

Frontiers in Microbiology
IntroductionEravacycline (ERV), a novel tetracycline derivative, exhibits broad-spectrum antibacterial activity, but data on the bacterial activity against Chinese bacterial isolates are very scarce.
Xiaoyan Liao, Qianwen Liang, Xinlu Dai, Shigang Wu, Chaohui Duan, Zhaofan Luo, Xiaoying Xie   +6 more
doaj   +2 more sources

Comparative efficacy of eravacycline and tigecycline in addressing multidrug-resistant Gram-negative bacteria

One Health Advances
The rise in antibiotic resistance among Gram-negative bacteria poses significant challenges to global health. This study evaluates the in vitro efficacy of tigecycline, omadacycline, and eravacycline against clinical isolates harboring the mobile ...
Jing Zhang, Hanyu Wang, Aoxiao Chen, Ning Dong, Hongwei Zhou, Kewei Li   +5 more
doaj   +2 more sources

Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022

Microbiology Spectrum
Eravacycline is a synthetic fluorocycline approved by the U.S. Food and Drug Administration in 2018. This study aimed to describe clinical and microbiological outcomes in addition to associated adverse effects of eravacycline used in U.S. hospitals. Real-
Ashlan J. Kunz Coyne, Sara Alosaimy, Kristen Lucas, Abdalhamid M. Lagnf, Taylor Morrisette, Kyle C. Molina, Alaina DeKerlegand, Melanie Rae Schrack, S. Lena Kang-Birken, Athena L.V. Hobbs, Jazmin Agee, Nicholson B. Perkins, Mark Biagi, Michael Pierce, James Truong, Justin Andrade, Jeannette Bouchard, Tristan Gore, Madeline A. King, Benjamin M. Pullinger, Kimberly C. Claeys, Shelbye Herbin, Reese Cosimi, Serina Tart, Michael P. Veve, Bruce M. Jones, Leonor M. Rojas, Amy K. Feehan, Marco R. Scipione, Jing J. Zhao, Paige Witucki, Michael J. Rybak   +31 more
doaj   +2 more sources

Investigation of the in vitro antimicrobial activity of eravacycline alone and in combination with various antibiotics against MDR Acinetobacter baumanni strains

BMC Microbiology
Background Acinetobacter baumannii is an obligately aerobic, non-motile, non-fermenting, gram-negative, opportunistic pathogen. The fact that this pathogen, which is the leading cause of nosocomial infections, is naturally resistant to many antibiotics ...
Merve Ataman, Berna Özbek Çelik
doaj   +2 more sources

In vitro activity of meropenem-vaborbactam combinations and eravacycline against carbapenem-resistant Acinetobacter baumannii [PDF]

Scientific Reports
Treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) presents a growing clinical challenge. This study evaluated the in vitro efficacy of eravacycline and the potential synergistic activity of meropenem-vaborbactam in combination with either ...
Amira H. El-Ashry, Ahmed Mostafa Abdrabou, Nora El-Tantawy, Rasha Mahmoud, Rasha El-Mahdy   +4 more
doaj   +2 more sources